anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Fetal MRI has become a critical tool for both studying the early development of the human brain and resolving diagnostic ambiguities that may remain after routine ultrasound exams. Due to its excellent soft-tissue contrast and the absence of harmful ionizing radiation, MRI is preferable to computed tomography for neuroimaging. Unfortunately, fetal and maternal motion limit fetal MRI to rapid two-dimensional (2D) sequences with thick slices such as half-Fourier single-shot turbo spin echo (HASTE). Although these sequences decrease the impact of motion during the sub-second acquisition of individual slices, multiple slices are needed, and contiguous orthogonal scans are challenging as motion occurs between slices. Typically, \>38% of acquisitions are discarded because of corrupted geometry and artifacts.

In this project the investigators will develop software that runs on the Siemens MRI scanner. This software will improve the workflow for fetal imaging i.e. for imaging the fetus in utero. Fetal imaging in its current form is inefficient due to the frequent motion of the fetus during the imaging procedure. In this project the investigators will develop automated methods for alignment and tracking of the fetus during imaging, to more efficiently image the fetus and to obtain better image quality in a shorter examination. The investigators are specifically interested in the fetal brain, but these methods may be generalized to all fetal organ systems. The investigators will install the software on the scanner and test these methods with volunteers.
All enrolled subjects will undergo breast reduction or breast mastectomy in which scar assessment will be made after pre-surgical treatment in a split-body design, involving a single treatment of RF application to one side of the surgical area(s) within 24 hours prior to the procedure. The subject will act as their own control, where one surgical area will be treated, and the other will not be and will act as the control. Tissue samples will be biopsied from RF treated skin, as well as non-treated skin, at follow up visits. The samples will be used for histological evaluation to assess tissue structure and regeneration following surgery.
A 0.9% bag of sodium chloride will be administered intravenously. Participant will be given a self-administered alcoholic drink of their choice that is individually calculated, and they will receive money up to $15 for every minute they resist drinking.
This is a prospective single center phase II study of a reduced intensity conditioning based hematopoietic cell transplant for patients with sickle cell disease. In this study, patients with SCD who would be expected to benefit from an allogeneic HCT will receive an unmanipulated peripheral blood derived hematopoietic stem and progenitor cell (HSPC) graft from either an MSD or HAPLO donor after a reduced intensity conditioning regimen comprising of alemtuzumab, thiotepa and low dose total body irradiation. All patients will receive a pre-conditioning phase comprising of hydroxyurea and azathioprine to reduce the risk of graft rejection. GVHD prophylaxis will consist of sirolimus. Patients on the HAPLO arm will also receive two doses of post-transplant cyclophosphamide. All patients will receive regularly scheduled low dose donor lymphocyte infusions till donor lymphocyte chimerism reaches at least 90% donor. The main objective of this study is to improve graft function and immune reconstitution after a reduced intensity conditioning based transplant.
Patients in this group recruited also in APPAC III trial will receive i.v. placebo 3 times per day for 3 days followed by p.o. placebo 3 times per day for 4 additional days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.
The relationship among gut microbiota, mitochondrial dysfunction/neuroinflammation, and diabetic neuropathic pain (DNP) has received increased attention. Ginger has antidiabetic and analgesic effects because of its anti-inflammatory property. We examined the effects of gingerols-enriched ginger (GEG) supplementation on pain-associated behaviors, gut microbiome composition, and mitochondrial function and neuroinflammation of colon and spinal cord in DNP rats. Thirty-three male rats were randomly divided into 3 groups: control group, DNP group (high-fat diet plus single dose of streptozotocin at 35 mg/kg body weight, and GEG group (DNP+GEG at 0.75% in the diet for 8 weeks). Von Frey and open field tests were used to assess pain sensitivity and anxio-depressive behaviors, respectively. Colon and spinal cord were collected for gene expression analysis. 16S rRNA gene sequencing was done from cecal samples and microbiome data analysis was performed using QIIME 2. GEG supplementation mitigated mechanical hypersensitivity and anxio-depressive behavior in DNP animals. GEG supplementation suppressed the dynamin-related protein 1 protein expression (colon) and gene expression (spinal cord), astrocytic marker GFAP gene expression (colon and spinal cord), and tumor necrosis factor-α gene expression (colon, P < .05; spinal cord, P = .0974) in DNP rats. GEG supplementation increased microglia/macrophage marker CD11b gene expression in colon and spinal cord of DNP rats. GEG treatment increased abundance of Acinetobacter, Azospirillum, Colidextribacter, and Fournierella but decreased abundance of Muribaculum intestinale in cecal feces of rats. This study demonstrates that GEG supplementation decreased pain, anxio-depression, and neuroimmune cells, and improved the composition of gut microbiomes and mitochondrial function in rats with diabetic neuropathy.
The effects of SAPHRIS on the QT/QTc interval were evaluated in a dedicated adult QT study. This trial involved SAPHRIS doses of 5 mg, 10 mg, 15 mg, and 20 mg twice daily, and placebo, and was conducted in 151 clinically stable patients with schizophrenia, with electrocardiographic assessments throughout the dosing interval at baseline and steady state. At these doses, SAPHRIS was associated with increases in QTc interval ranging from 2 to 5 msec compared to placebo. No patients treated with SAPHRIS experienced QTc increases ≥60 msec from baseline measurements, nor did any patient experience a QTc of ≥500 msec.

Electrocardiogram (ECG) measurements were taken at various time points during the SAPHRIS clinical trial program (5 mg or 10 mg twice daily doses). Post-baseline QT prolongations exceeding 500 msec were reported at comparable rates for SAPHRIS and placebo in these short-term trials. There were no reports of Torsade de Pointes or any other adverse reactions associated with delayed ventricular repolarization.

The use of SAPHRIS should be avoided in combination with other drugs known to prolong QTc including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and antibiotics (e.g., gatifloxacin, moxifloxacin). SAPHRIS should also be avoided in patients with a history of cardiac arrhythmias and in other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval, including bradycardia; hypokalemia or hypomagnesemia; and presence of congenital prolongation of the QT interval.
Optimal therapy for the growing number of patients with lenalidomide (LEN)-refractory multiple myeloma in their first relapse remains poorly defined. We therefore undertook a randomized phase 2 study to evaluate the efficacy and safety of combining the oral proteasome inhibitor ixazomib (IXA) with pomalidomide (POM) and dexamethasone (DEX) in this patient population. The overall response rate (ORR) for POM-DEX was 43.6%, and for IXA-POM-DEX, it was 63.2%. The depth of response, measured by the attainment of at least a very good partial response, favored triplet therapy over doublet therapy (28.9% vs 5.1%; P = .0063). A preplanned interim analysis after 75% of the progression events had occurred demonstrated an improvement in progression-free survival (PFS) that favored IXA-POM-DEX and that crossed the predefined boundary of superiority, leading to release of the study results. With additional follow-up, the median PFS for POM-DEX was 7.5 months (95% confidence interval [CI], 4.8-13.6 months) vs 20.3 months for IXA-POM-DEX (95% CI, 7.7-26.0 months; hazard ratio, 0.437; upper 90% bound = 0.657). The ORR and median PFS for 26 of 30 eligible patients who crossed over from the doublet to the triplet therapy at disease progression was 23.1% and 5.6 months, respectively. Overall survival was similar between the 2 groups. More hematologic toxicities were seen with the triplet therapy, but nonhematologic adverse events were similar between the 2 arms. Our data support further testing of this all-oral triplet therapy in comparison with current standard triplet therapy in the context of phase 3 studies for patients with LEN-refractory disease at first relapse. This trial was registered at www.clinicaltrials.gov as #NCT02004275.
A computer-implemented method, computer program product, and computing system for source separation is executed on a computing device and includes obtaining encounter information of a user encounter, wherein the encounter information includes first audio encounter information obtained from a first encounter participant and at least second audio encounter information obtained from at least a second encounter participant. The first audio encounter information and the at least second audio encounter information are processed to eliminate audio interference between the first audio encounter information and the at least second audio encounter information.A computer-implemented method, computer program product, and computing system for compartmentalizing a virtual assistant is executed on a computing device and includes obtaining encounter information via a compartmentalized virtual assistant during a user encounter, wherein the compartmentalized virtual assistant includes a core functionality module. One or more additional functionalities are added to the compartmentalized virtual assistant on an as-needed basis.A computer-implemented method, computer program product, and computing system for functionality module communication is executed on a computing device and includes obtaining encounter information via a compartmentalized virtual assistant during a user encounter, wherein the compartmentalized virtual assistant includes a plurality of functionality modules. At least a portion of the encounter information may be processed via a first functionality module of the plurality of functionality modules to generate a first result. The first result may be provided to a second functionality module of the plurality of functionality modules. The first result set may be processed via the second functionality module to generate a second result.A computer-implemented method, computer program product, and computing system for synchronizing machine vision and audio is executed on a computing device and includes obtaining encounter information of a user encounter, wherein the encounter information includes machine vision encounter information and audio encounter information. The machine vision encounter information and the audio encounter information are temporally-aligned to produce a temporarily-aligned encounter recording.
BACKGROUND: Cerebral infarctions resulting from iatrogenic air embolism (AE), mainly caused by small air bubbles, are a well-known and often overlooked event in endovascular interventions. Despite their significance, the underlying pathophysiology remains largely unclear.
METHODS: In 24 rats, AEs were induced using a microcatheter, positioned in the carotid artery via femoral access. Rats were divided into two study groups, based on the size of the bubbles (85 and 120 µm) and two sub-groups, differing in air volume (0.39 and 0.64 µl). Ultra-high-field magnetic resonance imaging (MRI) was performed 1.5 hours after intervention. MRI findings including the number, single volume and total volume of the infarctions were assessed. A software-based numerical simulation was performed to qualitatively assess the microvascular pathomechanisms.
RESULTS: In the study groups 22 of 24 rats (92%) revealed cerebral infarctions. The number of infarctions per rat was higher for the smaller bubbles, for the lower (medians: 5 vs 3; p=0.049) and higher air volume sub-groups (medians: 6 vs 4; p=0.012). Correspondingly, total infarction volume was higher for the smaller bubbles (1.67 vs 0.5 mm³; p=0.042). Simulations confirmed the results of the experiments and suggested that fusion of microbubbles to larger bubbles is the underlying pathomechanism of vascular occlusions.
CONCLUSION: In iatrogenic AE, the size of the bubbles can have a major impact on the number and total volume of cerebral infarctions. These findings can help to better understand the pathophysiology of this frequent, often underestimated adverse event in endovascular interventions.
A physiotherapist teaches exercises to participants (5 sessions of 20 minutes each of stretching and strengthening exercises). Exercises are focused on cervical and dorsal areas, Participants receive instructions to continue at home on a daily basis for 3 months. Participants receive a logbook that should be filled every day.
FIELD: medicine, stomatology. SUBSTANCE: cotton insertion material should be impregnated with the solution of official Yox's preparation dissolved with distilled water at 1:10 ratio. The former should be introduced with the help of a probe into all parodontal chambers. At availability of deep pouches and steady suppuration cotton insertion material should be changed twice or thrice during a seance. Treatment is carried out daily for 5-10 d. EFFECT: higher efficiency of therapy. 2 ex, 1 tbl
Primary end-point: The incidence of CMV infection or disease during the first year of transplantation.Secondary main end-point: the incidence of treatment failure defined as a composite end-point of BCAR, graft loss, death, loss to follow up.

The investigators anticipate enrolling 300 patients within 12 months. Only low risk adult candidates for first renal transplants from living or deceased donors will be considered for enrollment. Patients will be excluded if they have been receiving immunosuppressive therapy before transplantation; have received an investigational medication within the past 30 days; have a known contraindication to the administration of antithymocyte globulin; if tested positive for human immunodeficiency virus (HIV); if had had cancer (except nonmelanoma skin cancer) within the previous 2 years. Pregnant women, nursing mothers, and women of childbearing potential who will be not using condoms or oral contraceptives will be excluded. Patients with any panel reactive antibody (PRA) equal to or above 50%, class I or class II, will also be excluded. Study visits will be performed at pre transplant, days 0, 1, 7, every week up to month 6 and month 12.
The invention discloses an extrusion feeding device of an extrusion feeding devices of a skin care product containing biological microcrystal structure having a cylindrical container, a nozzle, an extrusion device and a protection cover. The cylindrical container is formed with an inner space. The inner space is filled with contains. The nozzle is located at one end of the cylindrical container and formed with a hole connected to the inner space. The extrusion device extends into the inner space for pushing the contents out of the inner space through the hole. The protective cover removably covers the nozzle and the hole.
<P>PROBLEM TO BE SOLVED: To provide populations of neural cells bearing markers of glial cells, such as oligodendrocytes and the precursor cells thereof.  <P>SOLUTION: The cell populations are generated by differentiating pluripotent stem cells such as human embryonic stem cells under conditions that promote enrichment of cells with the desired phenotype or functional capability. The cell populations bearing markers of oligodendrocyte precursor cells can be produced by using various combinations of differentiation factors and mitogens can be used to produce cell populations. Upon further differentiation, complex projections characteristic of mature oligodendrocytes are formed. The cells are capable of forming myelin sheaths, and can be used for therapeutic improvement of function of the central nervous system.  <P>COPYRIGHT: (C)2011,JPO&INPIT
INCB123667 will be administered at the recommended dose or doses for expansion (RDE\[s\]) for advanced or metastatic solid tumors. Participants with gastric, Gastro Esophageal Junction (GEJ), and esophageal adenocarcinomas will enroll in this group.
The present invention relates to a Chinese patent medicine for curing gastropathy and strengthening the stomach. Said medicine composition is composed of (by weight portion) 1-4 portions of mujiangcao and 1-2 portions of perilla stem, leaf and calyx. Its preparation method includes the following steps: cleaning raw material mujiangcao and perilla stem, leaf and calyx, adding water and decocting them for 30 min. to 2 hr. by using low flame, filtering and removing residue so as to obtain finished product. The Chinese medicinal materials of walnut or black chicken also can be added and decocted with above-mentioned materials according to the requirements. Its therapeutic effect is good, and it is simple in prescription, and has no side effect for human body.
The invention discloses a preparation method of calcium carbonate vitamin D3 chewable tablets, which relates to the technical field of medicines and aims to solve the problems of poor stability of vitamin D3, great influence by environment and unfavorable production and storage, and the preparation method comprises the following steps: 1) preparing vitamin D3 powder. 2) Weighing raw and auxiliary materials according to the prescription amount for later use. 3) A10% K30-pigment solution was prepared using a 20% ethanol aqueous solution. 4) Putting calcium carbonate and mannitol into a wet granulator, pouring K30-pigment solution for granulation, drying and granulating. 5) And (4) mixing the granules obtained in the step (5) with other materials, and tabletting. The vitamin D3 powder prepared by the invention is not easy to photolyze and oxidize, has high thermal stability and greatly reduces the production cost. The prepared tablet has good taste and convenient carrying, and increases the compliance of patients. The invention is used in the field of medicine preparation.
All participants to this study are being observed as a follow up to a previous study which involved 4 arms. All participants to this follow up study will be subject to identical study procedures.
PROBLEM TO BE SOLVED: To obtain the subject preparation capable of being rapidly collapsed and dissolved in an oral cavity and having practically durable hardness by dissolving and dispersing a medicine, a saccharide and polyvinyl pyrrolidone in an organic solvent and subsequently removing the organic solvent. SOLUTION: This preparation is obtained by dissolving and dispersing (A) a medicine (e.g. a medicine for central nervous systems, such as a sedative hypnotic, a medicine for peripheral nervous systems, such as an autonomic medicine), (B) a saccharide (e.g. a monosaccharide, a disaccharide, an oligosaccharide) and (C) polyvinyl pyrrolidone in (D) an organic solvent (especially preferably ethanol) and subsequently removing the component D. The components A, B and C are preferably compounded in amounts of <=60 wt.%, >=40 wt.% and 1-20 wt.%, respectively, based on the total solid content of the preparation. The preparation can be prepared e.g. by dissolving and dispersing the component D to the mixture powder of the components A-C, charging the suspension into a desired preparation template, and subsequently drying the molded product.
Dermatitis herpetiformis is a cutaneous manifestation of celiac disease. Phenotyping of intraepithelial lymphocytes in the small bowel mucosa can strengthen the diagnosis of celiac disease when it is not clear-cut. We aim to evaluate the usefulness of the intraepithelial lymphogram to confirm dermatitis herpetiformis in equivocal cases. We performed a retrospective multicenter study on patients diagnosed with dermatitis herpetiformis and collected data from the intraepithelial lymphogram assessed by flow cytometry. A total of 36 patients were analyzed in relation to the severity of intestinal damage (18 had non-atrophic mucosa) at baseline (N = 28) and/or after the adoption of a gluten-free diet (median follow-up of three years, N = 16). We observed that patients with atrophy more often had positive celiac serology (p = 0.019), celiac clinical symptoms (p = 0.018), and iron-deficiency anemia (p = 0.018), but the severity of skin damage was similar in both groups (p = 0.79). At baseline, increased TCRγδ+ cells were present in 94% of patients with atrophy and 67% with non-atrophic lesions (p = 0.13). After a gluten-free diet, increased TCRγδ+ cells persisted in 100% and 63% of cases, respectively (p = 0.21). We concluded that increased TCRγδ+ cells may be helpful in confirming the diagnosis of dermatitis herpetiformis in equivocal cases, even in patients who were started on a gluten-free diet.
First dose of 300 mg Ofatumumab followed by seven weekly infusions of 2000 mg. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.
<P>PROBLEM TO BE SOLVED: To provide an emergency transmission system that enables a paramedic to quickly and precisely report a patient's symptoms by means of an electronic pen when performing an emergency aid procedure according to a doctor's instructions.  <P>SOLUTION: In the emergency transmission system 100, the paramedic writes a patient's symptoms on a symptom fill-out form 3 using the electronic pen 10 inside an emergency vehicle or the like. Then the electronic pen 10 obtains written information corresponding to details written on the symptom fill-out form 3 and sends this information to a server 6 via a mobile terminal 5. Next, based on the written information obtained, the server 6 generates the image data of a stroke written on the symptom fill-out form 3 with the electronic pen 10, and saves the data. Further, the server 6 sends the image data of the stroke to a hospital terminal 7. Based on the image data obtained from the server 6, the hospital terminal 7 displays the image of the stroke on a display or the like.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Personal information form, Motherhood Blues Scale and Breastfeeding Self-Efficacy Scale will be applied for pre-test to women who meet our study criteria. After 10 days, the motherhood blues scale and breastfeeding self-efficacy scale will be administered again for the final test.
Metastasis is the greatest clinical challenge for UTUCs, which may have distinct molecular and cellular characteristics from earlier cancers. Herein, we provide single-cell transcriptome profiles of UTUC para cancer normal tissue, primary tumor lesions, and lymphatic metastases to explore possible mechanisms associated with UTUC occurrence and metastasis. From 28,315 cells obtained from normal and tumor tissues of 3 high-grade UTUC patients, we revealed the origin of UTUC tumor cells and the homology between metastatic and primary tumor cells. Unlike the immunomicroenvironment suppression of other tumors, we found no immunosuppression in the tumor microenvironment of UTUC. Moreover, it is imperative to note that stromal cells are pivotal in the advancement of UTUC. This comprehensive single-cell exploration enhances our comprehension of the molecular and cellular dynamics of metastatic UTUCs and discloses promising diagnostic and therapeutic targets in cancer-microenvironment interactions.